Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...

United Therapeutics' pipeline and Tyvaso DPI drive strong growth. Read why UTHR stock offers substantial upside with ...

Q3 2024 Earnings Call Transcript November 6, 2024 UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.55, ...

Third quarter global net product sales of $90.3 million; 2024 guidance increased to $330 - 335 million Volixibat granted ...

Alnylam Pharmaceuticals Inc (ALNY) reports impressive 34% year-over-year revenue growth, advances in clinical programs, and ...

Royalty Pharma PLC (RPRX) reports robust 15% growth in portfolio and royalty receipts, raises full-year guidance, and continues strategic acquisitions.

Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 mil ...

Q3 2024 Earnings Call Transcript November 6, 2024 Royalty Pharma plc misses on earnings expectations. Reported EPS is $0.918 ...

Sun Pharma's JAK inhibitor Leqselvi was slapped ... with execs warning of more obstacles ahead The Gardasil HPV vaccine franchise continued its decline for Merck & Co. because of lower demand ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...